Group 1 - The company Baoland announced that it will hold its first extraordinary general meeting of shareholders in 2025 on August 25, 2025 [1] - The agenda for the meeting includes the proposal to use remaining raised funds to permanently supplement working capital among other proposals [1]

Core Points - The Shanghai Suochen Information Technology Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals related to stock incentive plans and corporate governance [1][2]. Meeting Guidelines - The meeting will ensure the verification of attendees' identities and requires shareholders or their agents to arrive 30 minutes early for registration [3]. - Attendees must present necessary documents such as securities account cards and identification to participate in the meeting [3]. - The meeting will follow a structured agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [4][5]. Agenda Items - The agenda includes the review and voting on several proposals, including the 2025 Restricted Stock Incentive Plan and its management measures [7][8]. - The proposals aim to enhance the company's long-term incentive mechanisms and ensure alignment of interests among shareholders and the core team [9][10]. Proposals Overview - Proposal 1: The 2025 Restricted Stock Incentive Plan aims to attract and retain talent while aligning interests among stakeholders [9]. - Proposal 2: The management measures for the implementation of the 2025 Restricted Stock Incentive Plan are designed to ensure its smooth execution [10]. - Proposal 3: Authorization for the board to handle matters related to the 2025 Restricted Stock Incentive Plan [11]. - Proposal 4: The use of CNY 404.05 million of raised funds to permanently supplement working capital, representing 30% of the total raised funds [12][13]. - Proposal 5: Amendments to the company's articles of association, including the dissolution of the supervisory board and the transfer of its powers to the audit committee of the board [14]. - Proposal 6: Revisions to certain governance systems to enhance operational standards and protect shareholder rights [15].

Group 1 - The core point of the announcement is that the supervisory board of Chongqing Xishan Technology Co., Ltd. has approved the use of part of the raised funds for permanent replenishment of working capital, which is believed to enhance the efficiency of fund utilization [1][2] - The supervisory board meeting was convened with all three supervisors present, and the decision was made in accordance with the Company Law and the company's articles of association [1] - The resolution passed with unanimous support, indicating a strong consensus among the supervisory board members [2] Group 2 - The proposal to use part of the raised funds for working capital will be submitted to the shareholders' meeting for further approval [2] - The supervisory board confirmed that this action does not alter the intended use of the raised funds and does not harm the interests of the company or its shareholders [1]

Summary of Key Points Core Viewpoint - The company intends to use part of the excess raised funds to permanently supplement its working capital, which is expected to enhance operational efficiency and reduce financial costs while ensuring that the funding needs for investment projects are met [1][3][6]. Group 1: Fundraising Overview - The company successfully issued 10,333,400 shares at a price of 245.56 RMB per share, raising a total of 2,537,469,704 RMB, with a net amount of 231,574.91 million RMB after deducting issuance costs [1][5]. - The total amount of excess funds raised is 134,684.55 million RMB, which is subject to regulatory guidelines regarding the use of excess funds [5]. Group 2: Investment Project Details - The company plans to invest in the construction of 260 DEMX underwater noise testing instruments, with a total investment of 103,480.36 million RMB, of which 96,890.36 million RMB will be funded from the raised capital [2]. Group 3: Use of Excess Funds - The company proposes to use 40,405.00 million RMB of the excess funds, which accounts for 30% of the total excess funds, to supplement working capital [3][4]. - The company has committed that the cumulative use of excess funds for working capital or repaying bank loans will not exceed 30% of the total excess funds within any twelve-month period [4][5]. Group 4: Approval Process - The proposal to use part of the excess funds for working capital has been approved by the company's board of directors and supervisory board, and it will be submitted for shareholder approval [5][6]. - The supervisory board believes that this use of funds aligns with the company's operational needs and will not harm the interests of shareholders, particularly minority shareholders [6].

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - The meeting will include a combination of on-site and online voting, with each share having one vote [3][4] - The company plans to use part of its excess raised funds, totaling 639 million yuan, to permanently supplement its working capital, which accounts for 29.99% of the total excess funds of 2.13079 billion yuan [5][6] - The company has committed to using the raised funds only for its main business operations and will not exceed 30% of the total excess funds within a twelve-month period [6][7] Meeting Procedures - Shareholders must register 30 minutes before the meeting and present necessary identification to participate [1][2] - Shareholders have the right to speak, inquire, and vote during the meeting, but must register in advance to speak [2][3] - The meeting will follow a specific agenda, including the announcement of attendance, reading of meeting rules, and voting on proposals [4][5] Proposals - The first proposal involves using part of the excess raised funds for working capital, which has been approved by the board and supervisory board [5][6] - The second proposal includes changing the company's registered capital and amending the articles of association, which has also been approved by the board [6][7] - The company plans to distribute cash dividends and increase share capital based on the 2024 profit distribution plan [7]

Summary of Key Points Core Viewpoint - The company, Guokai Hengtai (Beijing) Medical Technology Co., Ltd., is utilizing part of its oversubscribed funds to permanently supplement its working capital, which has been approved by its board and supervisory committee, and is awaiting shareholder approval [1][5]. Group 1: Fundraising Overview - The company was approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with a net amount of RMB 843.209 million after deducting issuance costs of RMB 102.125 million [1][2]. - The funds were fully received by July 5, 2023, and are being managed in a dedicated account with a tripartite supervision agreement in place [2]. Group 2: Use of Oversubscribed Funds - The company held meetings on August 2, 2023, and August 18, 2023, to approve the use of RMB 136.5 million of oversubscribed funds for permanent working capital [2][4]. - The plan includes using RMB 68.25 million, which constitutes approximately 30% of the total oversubscribed funds, to enhance liquidity and improve financial efficiency [4]. Group 3: Compliance and Approval Process - The use of oversubscribed funds will not conflict with the implementation of fundraising investment projects and complies with relevant regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange [4][5]. - The supervisory committee has agreed that this use of funds will not harm the interests of the company or its shareholders, and the proposal is pending approval from the shareholders' meeting [5][6].

Core Points - The company held its second board meeting on June 19, 2025, to discuss amendments to the company's articles of association and governance rules [1][3][6] - The board approved multiple governance documents and proposed to submit these changes to the first extraordinary general meeting of shareholders in 2025 for further approval [3][6][7] Board Meeting Decisions - The board approved the revision of the company's articles of association and authorized management to handle related registration and filing procedures after shareholder approval [1][3] - The following governance documents were revised and approved: - Shareholders' meeting rules [3] - Board meeting rules [3] - Audit committee meeting rules [4] - Nomination committee meeting rules [4] - Compensation and assessment committee meeting rules [4] - Related party transaction decision-making system [4] - Independent director working system [4] - Fund management system [4] - Independent director special meeting working system [5] - General manager working rules [5] - Board secretary working rules [5] - External guarantee management system [5] - External investment management measures [5] - Information disclosure management system [5] - Investor relations management system [5] - Insider information registrant management system [6] - Internal audit system [6] - Public opinion management system [6] - Management system for departing directors and senior management [6] Financial Decisions - The board agreed to use 42 million yuan of raised funds to permanently supplement working capital, ensuring that the funding needs for investment projects are met [6][7] - The board decided to hold the first extraordinary general meeting of shareholders on July 8, 2025, to discuss the approved proposals [7]

Group 1 - The company held its 18th meeting of the third supervisory board on June 13, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The supervisory board approved the proposal to use up to RMB 900 million of idle raised funds and up to RMB 3.5 billion of idle self-owned funds for cash management, ensuring that it does not affect the company's normal operations or fundraising plans [1][2] - The board also approved the use of remaining over-raised funds to permanently supplement working capital, which aligns with regulatory requirements and aims to improve fund utilization efficiency and reduce financial costs [2]

Fundraising Situation - The company raised a total of RMB 917.70 million from the issuance of 38.80 million shares at a price of RMB 60.84 per share, with the net proceeds verified by an accounting firm [2] - The funds are stored in a special account with a regulatory agreement in place to monitor their usage [2] Fund Usage - The company plans to use the raised funds for several projects, including the All-Spectrum Precision Lens Intelligent Manufacturing Base and AI Optical Sensing Device R&D, with a total investment of RMB 766.28 million and a fundraising allocation of RMB 657.35 million [2] - The company has approved the use of RMB 31.13 million to replace self-raised funds and plans to inject RMB 250 million into its wholly-owned subsidiary, Fuguang Tiantong [3] Project Adjustments - The company has made several adjustments to its projects, including changing the implementation location for the Prism Cold Processing Industrialization Project and extending the construction period for the AI Optical Sensing Device R&D project [4][5] - The company has also approved the termination of certain projects and the allocation of remaining funds for new investment projects [8] Use of Excess Funds - The company intends to use RMB 79.93 million of its excess funds for permanent working capital, which represents 29.98% of the total excess funds of RMB 266.62 million [11] - The company commits to not exceeding 30% of the total excess funds for permanent working capital within a 12-month period and will not engage in high-risk investments during this time [12] Approval Process - The board of directors has approved the use of excess funds for working capital, which will be submitted for shareholder approval [13] - The company has followed necessary procedures in compliance with relevant regulations regarding the use of excess funds [13]

Core Viewpoint - The company intends to use part of the excess raised funds to permanently supplement its working capital, which is expected to enhance operational efficiency and reduce financial costs while aligning with the interests of all shareholders [1][4][5]. Fundraising Overview - The company was approved to publicly issue 25,666,700 shares at a price of RMB 80.88 per share, resulting in a total fundraising amount of approximately RMB 606.21 million after deducting issuance costs [1]. - The total amount of excess funds raised is RMB 210.30 million [4]. Investment Project Details - The total investment for the projects funded by the raised capital is RMB 395.92 million, with the funds allocated for these projects detailed in the prospectus [2][3]. Plan for Using Excess Funds - The company plans to use RMB 63 million, which is 29.96% of the total excess funds, to permanently supplement its working capital, ensuring that the needs of the fundraising investment projects are met [4]. - The use of excess funds is in compliance with regulations, as the cumulative amount used for this purpose in the last 12 months does not exceed 30% of the total excess funds [4]. Commitments and Explanations - The company commits that the cumulative use of excess funds for working capital will not exceed the total excess funds within any 12-month period and will not engage in high-risk investments or provide financial assistance to entities outside of its controlling subsidiaries within the next 12 months [4]. Approval Process - The proposal to use part of the excess funds was approved in the company's board and supervisory meetings held on June 11, 2025, and is pending approval from the shareholders' meeting [5]. Supervisory and Sponsor Opinions - The supervisory board supports the use of excess funds for working capital, stating it will not affect the normal implementation of fundraising projects and will not harm the interests of the company and its shareholders [5]. - The sponsor institution has no objections to the company's plan to use excess funds for working capital, confirming compliance with relevant laws and regulations [5].